Mustafa Canbaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mustafa Canbaz has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ahmet Emin Erbaycu
Department of Pulmonology, Cigli Training and Research Hospital, Izmir Bakırçay University, 35620 Izmir, Türkiye
1 shared publication - Betül İkbal Doğan
Clinic of Chest Diseases, Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey
1 shared publication - Ceyda Anar
Department of Chest Diseases, Izmir Katip Çelebi University Atatürk Training and Resource Hospital, Basın Sitesi, Izmir, Turkey
1 shared publication - Ender Salbaş
Department of Physical Medicine and Rehabilitation, Balıkesir University Faculty of Medicine, Balıkesir, Türkiye
1 shared publication - Faruk Özşahin
Giresun University Education and Research Hospital
1 shared publication - Filiz Güldaval
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, İZMİR TIP FAKÜLTESİ, İZMİR TIP PR
1 shared publication
Latest Publications
- 15 June 2021
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 69 (2) , 133-143
Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/ lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
The aim of this study was to evaluate the predictive power of LENT (LDH in pleural fluid, Eastern Cooperative Oncology Group [ECOG] performance status, neutrophil-lymphocyte ratio in the serum, and tumor type) score which is a current prognostic score in patients with MPE and to determine its effect on survival and its status in clinical decision making. In addition, it was aimed to compare LENT score with the conventional but subjective score ECOG. A retrospective observational study was conducted reviewing the medical records of patients managed for MPE (malign pleural effusion) between 2008 and 2018. LENT prognostic score was calculated in the patients. The ECOG score calculated for the same patients was compared in terms of mortality. A total of 191 patients with malignant pleural effusion, 118 males (61.7%) and 73 females (38.2%), were included in the study. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying overall survival were 69.8 %, 100%, 100% and 18.8%, respectively at the LENT score > 4 (p= 0.000). At ECOG PS >2, the sensitivity, specificity, PPV, NPV were as the same as the LENT score >4 for identifying overall survival. In all patients, overall median survival according to the LENT score was 662/119/33 days in low/moderate/high risk groups, respectively. Cox regression analysis indicated that having a moderate LENT score (p= 0.004, OR: 2.21, CI: 1.29 -3.78%) and high LENT score (p= 0.000, OR: 4, 50 CI: 2.57-7.89%) were predictors for overall survival in all patients due to MPE. In ROC analysis, there was no difference in mortality in erms of both LENT and ECOG at 1st, 6th and 12th months. LENT is a better scoring system than ECOG in predicting early mortality, while both ECOG and LENT have almost the same power in predicting mortality. However, LENT is slightly more objective but more difficult to calculate because it contains laboratory findings. Thus, both scoring systems can be used to predict mortality in patients with malignant pleural effusions. Neither of them has superiority to each other.
- 15 June 2021
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 69 (2) , 133-143
Can LENT Prognostic score (LDH, ECOG performance score, blood neutrophil/ lymphocyte ratio, tumor type) change the clinical approach in malignant pleural effusion?
The aim of this study was to evaluate the predictive power of LENT (LDH in pleural fluid, Eastern Cooperative Oncology Group [ECOG] performance status, neutrophil-lymphocyte ratio in the serum, and tumor type) score which is a current prognostic score in patients with MPE and to determine its effect on survival and its status in clinical decision making. In addition, it was aimed to compare LENT score with the conventional but subjective score ECOG. A retrospective observational study was conducted reviewing the medical records of patients managed for MPE (malign pleural effusion) between 2008 and 2018. LENT prognostic score was calculated in the patients. The ECOG score calculated for the same patients was compared in terms of mortality. A total of 191 patients with malignant pleural effusion, 118 males (61.7%) and 73 females (38.2%), were included in the study. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for identifying overall survival were 69.8 %, 100%, 100% and 18.8%, respectively at the LENT score > 4 (p= 0.000). At ECOG PS >2, the sensitivity, specificity, PPV, NPV were as the same as the LENT score >4 for identifying overall survival. In all patients, overall median survival according to the LENT score was 662/119/33 days in low/moderate/high risk groups, respectively. Cox regression analysis indicated that having a moderate LENT score (p= 0.004, OR: 2.21, CI: 1.29 -3.78%) and high LENT score (p= 0.000, OR: 4, 50 CI: 2.57-7.89%) were predictors for overall survival in all patients due to MPE. In ROC analysis, there was no difference in mortality in erms of both LENT and ECOG at 1st, 6th and 12th months. LENT is a better scoring system than ECOG in predicting early mortality, while both ECOG and LENT have almost the same power in predicting mortality. However, LENT is slightly more objective but more difficult to calculate because it contains laboratory findings. Thus, both scoring systems can be used to predict mortality in patients with malignant pleural effusions. Neither of them has superiority to each other.
- Open Access
- 29 October 2020
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 4 (3) , 291-295
A Rare Cause of Interstitial Lung Disease in Rheumatology Clinic: Case Report for Sulfasalazine-Induced Acute Pulmonary Injury
Infection, primary lung pathology, rheumatic involvement, malignancy and drug-induced involvement can be suggested as differential diagnosis of a case with rheumatic disease who applied to an emergency service with pulmonary symptoms.The drugs cause 2.5-3% of interstitial lung diseases.Sulfasalazine has been widely used in the treatment of inflammatory rheumatic conditions and it is an extremely rare reason for interstitial lung disase. Here, we aimed to present the rarely seen sulfasalazine-induced interstitial pulmonary disease and its treatment. Sulphasalazine -induced lung disease can mimic the symptoms of infectious and rheumatic lung involvement and can cause serious diagnostic confusion.
- 29 October 2020
- Published by Acta Medica Alanya in Acta Medica Alanya
- Vol. 4 (3) , 291-295
Open AccessA Rare Cause of Interstitial Lung Disease in Rheumatology Clinic: Case Report for Sulfasalazine-Induced Acute Pulmonary Injury
Infection, primary lung pathology, rheumatic involvement, malignancy and drug-induced involvement can be suggested as differential diagnosis of a case with rheumatic disease who applied to an emergency service with pulmonary symptoms.The drugs cause 2.5-3% of interstitial lung diseases.Sulfasalazine has been widely used in the treatment of inflammatory rheumatic conditions and it is an extremely rare reason for interstitial lung disase. Here, we aimed to present the rarely seen sulfasalazine-induced interstitial pulmonary disease and its treatment. Sulphasalazine -induced lung disease can mimic the symptoms of infectious and rheumatic lung involvement and can cause serious diagnostic confusion.